189 GSK Annual Report 2018 Strategic report Governance and remuneration Financial statements Investor information 35.
Related party transactions At 31 December 2018, GSK owned 32 million shares or 31.7% of Innoviva Inc. which is a biopharmaceutical company listed on NASDAQ.
GSK began recognising Innoviva as an associate on 1 September 2015.
The royalties due from GSK to Innoviva in the year were 209 million 2017 173 million.
At 31 December 2018, the balance payable by GSK to Innoviva was 64 million 2017 53 million.
At 31 December 2018, GSK held a 50% interest in Japan Vaccine Co. Ltd JVC through its subsidiary GlaxoSmithKline K. K. This joint venture with Daiichi Sankyo Co. Ltd is primarily responsible for the development and marketing of certain prophylactic vaccines in Japan.
During 2018, GSK sold 43 million 2017 41 million of its vaccine products into the joint venture.
At 31 December 2018, the trading balance due to GSK from JVC was 15 million 2017 11 million and the balance payable by GSK to JVC was nil 2017 nil.
Loans of 5 million to Medicxi Ventures I LP and 6 million to Index Ventures Life VI Jersey LP remained due to GSK at 31 December 2018.
In 2018, GSK increased the equity investment in Kurma Biofund II, FCPR by 3 million, Apollo Therapeutics LLP by 2 million and Longwood Founders Fund LP by 0.2 million, and reduced a liability with Qura Therapeutics LLC by 3 million.
As at 31 December 2018, the outstanding liability to Qura was 4 million.
The aggregate compensation of the Directors and CET is given in Note 9, Employee costs.
Adjustments reconciling profit after tax to operating cash flows 2018 2017 2016 m m m Profit after tax 4,046 2,169 1,062 Tax on profits 754 1,356 877 Share of after tax profits of associates and joint ventures 31 13 5 Finance expense net of finance income 717 669 664 Depreciation 954 988 978 Amortisation of intangible assets 902 934 796 Impairment and assets written off 350 1,061 226 Profit on sale of businesses 63 157 5 Profit on sale of intangible assets 201 46 178 Profit on sale of investments in associates 3 94 Profit on sale of equity investments 4 37 254 Gain on Consumer Healthcare Joint Venture put hedging 513 Business acquisition costs 47 Changes in working capital: Decrease increase in inventories 51 461 70 Increase in trade receivables 429 287 188 Increase in trade payables 131 11 96 Decrease in other receivables 18 74 381 Contingent consideration paid see Note 984 594 358 Other non-cash increase in contingent consideration liabilities 1,250 961 2,281 Increase in other payables 2,362 1,741 1,989 Increase decrease in pension and other provisions 102 255 621 Share-based incentive plans 360 333 319 Fair value adjustments 7 3 Other 62 95 21 5,701 6,089 7,044 Cash generated from operations 9,747 8,258 8,106
